Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2024-03-11 AGM Information
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의) and a subsequent correction (정정신고) regarding the agenda items. It provides details on the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM). In the context of financial filings, documents that solicit votes or provide the formal notice and agenda for an upcoming shareholder meeting are classified as Proxy Solicitation & Information Statements (PSI).
2024-03-11 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Eyegene Inc. It includes the meeting date, location, agenda items (financial statements, director/auditor compensation, and articles of incorporation changes), and detailed management information regarding business operations, R&D, and market outlook. This document is a comprehensive information package provided to shareholders for the upcoming AGM, which fits the definition of Proxy Solicitation & Information Statement (PSI) as it contains the agenda, voting instructions, and detailed management reports required for shareholder decision-making.
2024-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with Form 14A-equivalent filings) used to solicit shareholder votes for an upcoming Annual General Meeting. It contains details about the meeting, the proxy solicitation process, and includes summary financial statements as part of the management's reference materials for shareholders. This fits the 'Proxy Solicitation & Information Statement' category.
2024-03-11 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company '아이진'. It outlines the date, location, and agenda items (such as approval of financial statements and director remuneration) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2024-03-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder and their special related parties, including the purpose of holding, transaction history, and contract details. This falls under the category of 'Major Shareholding Notification'.
2024-03-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by an executive (Choi Seuk Keun) of Eyegene Inc. through market purchases. This type of filing is specifically categorized as a Director's Dealing (DIRS) report, as it documents insider share transactions.
2024-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.